MiNK Therapeutics Reports Q2 2026 Financial Results

What Happened
MiNK Therapeutics, Inc. (INKT) announced its financial results for the quarter ended June 30, 2026 and furnished the related press release as Exhibit 99.1 to a Form 8‑K filed on August 13, 2026. The Form 8‑K reports Item 2.02 (Results of Operations and Financial Condition) and furnishes the press release under Item 9.01. The filing is signed by Jennifer S. Buell, President and Chief Executive Officer.

Key Details

• Announcement date: August 13, 2026.
• Reporting period: quarter ended June 30, 2026.
• Press release furnished as Exhibit 99.1 to the Form 8‑K.
• Form 8‑K signed by Jennifer S. Buell (President & CEO).

Why It Matters
This 8‑K tells investors that MiNK publicly released its quarterly financial results; the detailed numbers and commentary are contained in the press release (Exhibit 99.1). Investors should review that press release for revenue, profit/loss, cash position, and any management commentary or guidance changes, and watch for the company’s upcoming periodic filings (e.g., 10‑Q) for audited/complete financial statements and additional disclosures.